Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

485
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
485
Feedback Loops01:01

Feedback Loops

63.3K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
63.3K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

16.1K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

116
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
116
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

579
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
579
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

504
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
504

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gα<sub>q</sub> Is a Heterotrimeric G-Protein Subunit That Directs the Selectivity of PPARγ-Induced Gene Pathways Toward Energy-Related Processes Rather than Adiposity.

Metabolites·2026
Same author

Publisher Correction: GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Nature·2026
Same author

Lipid mobilization establishes metabolic tolerance and prevents autonomic collapse in infection.

bioRxiv : the preprint server for biology·2026
Same author

Hyaluronidase-1 mediates postprandial suppression of hepatic gluconeogenesis.

Life metabolism·2026
Same author

GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Nature·2026
Same author

Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging.

Nature aging·2026
Same journal

Adipose Tissue Overexpression of Nicotinamide Phosphoribosyltransferase Prevents Metabolic Dysfunction in Obese Mice via Extracellular Vesicles.

Diabetes·2026
Same journal

Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.

Diabetes·2026
Same journal

Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.

Diabetes·2026
Same journal

Targeting the ADA/ADO Axis Rescues β-Cell Failure in Type 2 Diabetes.

Diabetes·2026
Same journal

TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence.

Diabetes·2026
Same journal

Sex Differences in ER Stress Pathways Are a Key Determinant of β-Cell Proliferation and Resilience.

Diabetes·2026
See all related articles

Related Experiment Video

Updated: Dec 23, 2025

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing
05:45

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing

Published on: October 25, 2019

6.3K

Leptin: Less Is More.

Shangang Zhao1, Christine M Kusminski1, Joel K Elmquist2

  • 1Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.

Diabetes
|April 22, 2020
PubMed
Summary
This summary is machine-generated.

Hyperleptinemia, not leptin deficiency, causes leptin resistance and metabolic disorders in obesity. Reducing leptin levels may improve leptin sensitivity and action, offering a new therapeutic approach for obesity and type 2 diabetes.

More Related Videos

Author Spotlight: Hypothalamic Neural Mechanism Insights
09:29

Author Spotlight: Hypothalamic Neural Mechanism Insights

Published on: August 4, 2023

4.5K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

338

Related Experiment Videos

Last Updated: Dec 23, 2025

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing
05:45

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing

Published on: October 25, 2019

6.3K
Author Spotlight: Hypothalamic Neural Mechanism Insights
09:29

Author Spotlight: Hypothalamic Neural Mechanism Insights

Published on: August 4, 2023

4.5K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

338

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Obesity Research

Background:

  • Leptin therapy is effective for lipodystrophy and leptin deficiency.
  • Pharmacological leptin treatments for diet-induced obesity have shown limited success.
  • The phenomenon of 'leptin resistance' requires further investigation.

Purpose of the Study:

  • To propose a conceptual shift in understanding leptin resistance.
  • To explore the hypothesis that reduced bioactive leptin levels enhance leptin sensitivity.
  • To investigate partial leptin reduction as a potential therapeutic strategy for obesity and type 2 diabetes.

Main Methods:

  • Conceptual analysis based on recent data.
  • Exploration of underlying mechanisms of leptin action and resistance.
  • Discussion of partial leptin reduction as a therapeutic avenue.

Main Results:

  • Hyperleptinemia, rather than leptin deficiency, is implicated as a cause of leptin resistance.
  • Reduced bioactive leptin levels may lead to enhanced central and peripheral leptin sensitization and action.
  • This conceptual shift suggests a new therapeutic direction.

Conclusions:

  • A paradigm shift is needed to understand leptin resistance in obesity.
  • Partial leptin reduction may be a viable therapeutic strategy for obesity and type 2 diabetes.
  • Further research into partial leptin reduction therapy is warranted.